0001171843-13-002374.txt : 20130603 0001171843-13-002374.hdr.sgml : 20130603 20130603090117 ACCESSION NUMBER: 0001171843-13-002374 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130603 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130603 DATE AS OF CHANGE: 20130603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 13886906 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 8-K 1 document.htm FORM 8-K FILING DOCUMENT Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 3, 2013 

Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-15281 76-0233274
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer Identification No.)

2408 Timberloch Place, Suite B-7
The Woodlands, Texas		 77380
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:   (281) 719-3400

________________________________________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    [   ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [   ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [   ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [   ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On June 3, 2013 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

    Exhibit 99.1.       Press release dated June 3, 2013

SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Repros Therapeutics Inc.
(Registrant)
June 3, 2013
(Date)		   /s/   KATHI ANDERSON
Kathi Anderson
CFO

  Exhibit Index
  99.1 Press release dated June 3, 2013






EX-99 2 newsrelease.htm PRESS RELEASE Repros to Webcast Investor and Analyst Day on June 6th

EXHIBIT 99.1

Repros to Webcast Investor and Analyst Day on June 6th

THE WOODLANDS, Texas, June 3, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York on Thursday, June 6, 2013 beginning at 12:00 p.m. Eastern Time.

Key Opinion Leaders will discuss the positive data from the 1st completed Phase III study with Androxal®, ZA-301, and the significance of data from the AUA podium session. The focus of the participating inter-disciplinary group will be the role of Androxal in "managing the whole patient". In addition there will be a short overview of the Proellex®-V program.

Presenters include:

  • Michael G Wyllie, Ph.D., DSc. - Director of the Company
  • Andrew McCullough, M.D. - Professor of Urology/Division of Surgery, Albany Medical College: Urological Inst of North Eastern NY
  • John Dean, M.D. - Immediate past president of the International Society of Sexual Medicine, Harley St, London, UK
  • Larry Lipshultz, M.D. - Professor of Urology and Chief of the Division of Male Reproductive Medicine and Surgery at the Baylor College of Medicine in Houston, Texas
  • Edward Kim, Ph.D. – Professor at University of Tennessee Graduate School of Medicine
  • Glenn Cunningham, M.D. - Professor of Medicine and Molecular & Cellular Biology Baylor College of Medicine, Director, SLEH-BCM Diabetes Program
  • Andrew Dwyer - Project Department of Endocrinology, Diabetes and Metabolism Centre Hospitalier Universitaire Vaudois
  • Nelly Pitteloud, M.D. - Professor of Medicine, Co-Chief, Endocrinology, Diabetes and Metabolism Service, CHUV, Lausanne, Switzerland
  • Alfred Poindexter, M.D. - board certified physician and professor in the Department of Obstetrics and Gynecology at Baylor College of Medicine
  • Joachim F. Wernicke, Ph.D., M.D. – CMO of Repros
  • Jaye Thompson, Sr. VP Clinical & Regulatory of Repros

A live and archived webcast of the presentation will be available on the "Events" section of the Company's website, http://www.reprosrx.com.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs, have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com.

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer

         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931
         thoffmann@troutgroup.com